Web16 okt. 2024 · Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic ... Web31 aug. 2024 · Ionis and Akcea expect to complete the transaction in the fourth quarter of 2024, subject to other customary closing conditions. Ionis expects to fund the acquisition …
Ionis Pharmaceuticals - cointime.com
Web28 dec. 2024 · Akcea Therapeutics Ionis Pharmaceuticals, Inc. Study Documents (Full-Text) Documents provided by Akcea Therapeutics: Study Protocol and Statistical Analysis Plan [PDF] December 17, 2024 More Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Web7 dec. 2024 · AstraZeneca will pay Ionis an upfront payment of $200m and additional conditional payments of up to $485m following regulatory approvals. It will also pay up to … jay gatsby relationships
Akcea and Ionis Announce Closing of Licensing Agreement
Web8 okt. 2024 · Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug Pfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop … Web14 sep. 2024 · The combination of Ionis and Akcea accelerates the next phase of Ionis' growth and positions it to better deliver more medicines to patients while maximizing … Web1 jun. 2024 · Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing medicines to treat ... jay gatsby relationship to other characters